Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) Covered Calls

You can sell covered calls on Adaptimmune Therapeutics plc - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ADAP (prices last updated Fri 4:16 PM ET):

Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
0.59 0.00 0.59 0.60 3.4M - 0.0
Covered Calls For Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Dec 20 0.5 0.15 0.45 11.1% 113%
Jan 17 0.5 0.15 0.45 11.1% 63.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.